Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT06577519

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD (from the registry)
Registry
  • NCT NCT06577519
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06577519. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-06 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Condition
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI (percutaneous coronary intervention))
Intervention (Drug)
Vicagrel
Intervention (Drug)
Clopidogrel
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD (class: industry)

Record details

Record id
cardio:ct-nct06577519
Content hash
6f0203bfdc6bfffe76a0e896f9db809150faaccbaff89477e0a00bf7bda4a0ce